Introduction
Stem cells are defined, in general, by their ability to self-renew and differentiate into multiple lineages. Functionally, stem cell activity can be defined by several methods. Clonogenicity and multilineage differentiation in vitro are classical and convenient assays to demonstrate stemness and have been widely used to assess stem cell activity in various tissues. Genetic lineage tracing and long-term label-retaining assays have been used to identify and characterize stem cells in vivo. These assays have allowed extensive characterization of several tissue-specific stem cells, including intestinal stem cells, dermal stem cells, and hair follicle stem cells (Barker et al., 2012; Blanpain and Fuchs, 2009; Fuchs, 2009 ). Alternatively, long-term repopulation upon transplantation of a single sorted cell has been long regarded as the gold standard of stem cell activity in the hematopoietic compartment (Oguro et al., 2013; Smith et al., 1991) . The stem cell for the liver has been defined as the cell that gives rise to both hepatocytes and biliary epithelial cells (cholangiocytes), the two types of liver epithelial cells. Although there are many reports describing liver stem cells, the measures used to define liver stem cells have not necessarily been adequate in many cases. In this Review, we describe the defining characteristics used to describe liver stem cells and discuss the evidence supporting and refuting whether self-renewable and bipotential liver stem cells exist in development, homeostasis, and regeneration.
Liver Functions and Architecture
The liver is a central organ for homeostasis and carries out a wide range of functions, including metabolism, glycogen storage, drug detoxification, production of various serum proteins, and bile secretion. Since liver functions are essential for homeostasis, liver diseases, such as hepatitis, fibrosis, and cirrhosis, often result in morbidity and mortality. The liver is unique in its extraordinary capacity to regenerate from various injuries. Strikingly, the liver's ability to recover its original mass after surgical removal of a significant portion makes it possible to transplant liver tissue from a living donor. The basic architectural unit of the liver is the liver lobule, which is described in detail in Figure 1 .
Most of the metabolic and synthetic functions of the liver are carried out by hepatocytes, which account for approximately 60% of total liver cells and 80% of the volume of the organ. Hepatocytes are highly polarized epithelial cells and form cords. Their basolateral surfaces face fenestrated sinusoidal endothelial cells, facilitating the exchange of materials between hepatocytes and blood vessels. Tight junctions formed between hepatocytes create a canaliculus that surrounds each hepatocyte. Bile secreted from mature hepatocytes is exported sequentially through bile canaliculi surrounded by the apical membrane of neighboring hepatocytes, intrahepatic bile ducts, extrahepatic bile ducts, and, finally, the duodenum. The bile duct is formed by a specialized type of epithelial cell called a cholangiocyte.
Hepatoblasts as the Liver Progenitor Cell in Development
The onset of mouse liver development begins at embryonic day (E) 8.5 from the foregut endoderm, which is derived from medial and lateral domains of developing ventral foregut (Tremblay and Zaret, 2005) . The commitment of endoderm cells to the liver is dictated by two crucial cytokines: fibroblast growth factor (FGF) from the developing heart (Gualdi et al., 1996; Jung et al., 1999) and bone morphogenetic protein (BMP) from the septum transversum mesenchyme (STM) (Rossi et al., 2001 ). The foregut endoderm cells destined for hepatic fate begin to express transcription factors Hex and HNF4a as well as the liver-specific genes a-fetoprotein (AFP) and albumin (ALB) and migrate as cords into the surrounding STM. These cells are common progenitor cells, which give rise to both hepatocytes and cholangiocytes, and are called ''hepatoblasts'' during liver development. Historically, immunohistochemical analysis had been used to characterize hepatoblasts; however, specific cell surface markers for prospective isolation of hepatoblasts were not identified until more recently. Because the fetal liver is a major hematopoietic organ and blood cells occupy the majority of liver cells, a combination of negative selection by CD45 (common leukocyte antigen) and TER119 (erythroid cell antigen) and positive selection by some cell surface markers has been utilized to successfully isolate hepatoblasts. In many cases, the sorted cells from fetal liver were evaluated by the expression of liverspecific genes such as AFP and ALB, clonogenicity and bipotency in vitro, and their ability to repopulate adult liver upon transplantation. Suzuki et al. (2000) developed a single-cellbased assay called the hepatic colony-forming unit in culture (H-CFU-C) and showed that the CD45 -TER119 -c-Kit -CD29 + CD49f + fraction of E13.5 mouse liver contained colony-forming cells with the potential to differentiate into hepatocytic and cholangiocytic lineages. Since then, sorting for c-Kit low (Minguet et al., 2003) , c-Kit -c-Met + CD49f +/low (Suzuki et al., 2003) , CD13 + , or CD13 + c-Kit -CD49f
À/low CD133 + in combination with CD45 À and TER119 À has been applied to isolate the hepatoblast compartment. Alternatively, positive selection with a single specific marker has also been reported to isolate hepatoblasts. Deltalike 1 homolog (Dlk1), also known as Pref-1, is expressed in liver buds as early as E9.0 in mouse embryo and can also be used to isolate bipotential cells. Dlk1 expression is gradually decreased in the liver by the neonatal stage and becomes undetectable in adult liver. Dlk1 + cells isolated from E14.5 livers form highly proliferative colonies composed of the hepatocyte and cholangiocyte lineages in vitro (Tanimizu et al., 2003) . E-cadherin, an epithelial-specific marker, was also utilized to isolate hepatoblasts (Nitou et al., 2002; Nierhoff et al., 2005) . E12.5 liver epithelial cells were shown to specifically express E-cadherin, Dlk1, and Liv2, a unique marker for epithelial cells in the E9.5-E12.5 fetal liver (Watanabe et al., 2002) , and sorted E-cadherin + cells repopulated the liver after transplantation. Nierhoff et al. (2007) (Xu et al., 2011) . The expression profile of representative cell surface markers during liver development is illustrated in Figure 2 , and the characterization of hepatoblasts by prospective isolation is summarized in Table 1 . Engraftment of in vitro expanded hepatoblasts in adult mouse liver injury models can be used to demonstrate some aspects of stem cell activity. However, unlike long-term repopulation of a single sorted hematopoietic stem cell, which demonstrates self-renewal and multidifferentiation potential in mice, engraftment of hepatoblasts requires a large number of cells, with more than 5 3 10 4 cells needed to engraft a single mouse or rat Nierhoff et al., 2005; Oertel et al., 2008; Suzuki et al., 2000; Tanimizu et al., 2003) . In addition, engraftment of transplanted hepatoblasts to bile ducts has not necessarily been convincingly demonstrated, most likely because of the lack of an appropriate bile duct injury model to assess engraftment. Thus, transplantation studies using hepatoblasts do not provide sufficient evidence to fulfill the stringent criteria of ''stemness'' that is used for other stem cell types, such as hematopoietic stem cells.
Stem Cell Properties of Fetal Liver Cells
Several reports using culture systems have demonstrated the presence of a potential liver ''stem cell'' in the fetal liver, which has the capacity for unlimited proliferation and multilineage . Similar bipotential cell lines exhibiting the properties of liver stem cells were also obtained after a long latency period in culture of fetal liver cells, though their specific cellular origin was unknown (Strick-Marchand and Weiss, 2002; Tsuchiya et al., 2005) . One of the cell lines, referred to as BMEL (StrickMarchand and Weiss, 2002) , expresses hepatocytic transcription factors such as HNF1a, HNF4a, and GATA4, but not ALB. Because BMEL cell lines can be generated reproducibly, the bipotential progenitors provide a useful experimental model to study the mechanism of differentiation. Dan et al. (2006) established cells similar to those mouse cells-multipotent progenitor cells from human fetal liver cells in long-term culture named ''hFLMPCs,'' which exhibited capacities of self-renewal, multipotent differentiation, and repopulation in a mouse liver injury model. Intriguingly, the hFLMPCs expressed several stem-cell-related markers, such as CD90, c-Kit, CD44h, and EpCAM, but neither AFP nor ALB. Schmelzer et al. (2007) 
Mechanisms Underlying the Proliferation and Differentiation of Hepatoblasts
Proliferation and differentiation of hepatoblasts are supported and coordinated by various cell types in the liver during embryogenesis. Here, we focus on the cell-to-cell interactions relevant to the growth and differentiation of hepatoblasts into hepatocytes (Figure 2 ). At the earliest stage of liver development, hepatoblasts emerge from foregut endoderm and proliferate to form the liver bud in a process that requires Flk1 + endothelial cells in STM (Matsumoto et al., 2001) . At later stages, mesothelial cells (MCs), which form the mesothelium that covers the parenchyma and prevents adhesion with other tissues, express high levels of various growth factors for hepatocytes such as HGF, Midkine, and Pleiotrophin (Onitsuka et al., 2010) . Fetal MCs enhance proliferation of Dlk1 + hepatoblasts/immature hepatocytes in a coculture system. Wilms tumor 1 (WT1) is a transcription factor essential for development of MCs and the lack of WT1 impairs liver growth (Ijpenberg et al., 2007) . Together, these results indicate that immature MCs contribute to hepatoblast proliferation. By contrast, Thy1 + mesenchymal cells in the murine fetal liver promote the maturation of CD49f + hepatic progenitor cells by direct cell-to-cell contact in a coculture system (Hoppo et al., 2004) . Interestingly, human embryonic stem cell (ESC)-derived KDR + AFP À hepatic progenitors were shown to promote the maturation of KDR À AFP + hepatic cells in vitro, suggesting the possibility that a small population of hepatoblasts itself provides a niche for hepatic maturation (Goldman et al., 2013) . Hematopoietic cells start to colonize the liver in midgestation, and the fetal liver serves as the major hematopoietic tissue until the perinatal stage when hematopoiesis shifts to the bone marrow. Hepatoblasts/immature hepatocytes are closely associated with hematopoietic precursor cells and support hematopoiesis in fetal liver. Reciprocally, cytokines secreted from blood cells play a pivotal role for functional and morphological maturation of hepatocytes; e.g., Oncostatin M (OSM), an interleukin-6 family member, produced by hematopoietic cells promotes hepatocyte maturation in vitro by inducing the expression of several metabolic enzymes and the formation of adherens junctions (Kamiya et al., 1999 Matsui et al., 2002) . Hematopoiesis shifts from fetal liver to the bone marrow around birth, and metabolic and synthetic functions of the liver drastically change as reflected by the altered expression of various genes. Typically, xenobioticmetabolizing cytochrome P450 genes are highly upregulated in neonatal stages. However, the metabolic shift is not a uniform process. Even fully mature hepatocytes constitute heterogenous cell populations depending on their location within a hepatic lobule, which is referred to as ''metabolic zonation.'' A number of genes related to metabolism are differentially expressed in either the periportal or pericentral zone. Despite several studies investigating the involvement of Wnt/b-catenin signaling in metabolic zonation (Benhamouche et al., 2006; Burke et al., 2009; Sekine et al., 2006) , the responsible Wnt ligand remains unclear.
Mechanisms Regulating the Differentiation of Hepatoblasts into Cholangiocytes
In contrast to hepatocyte maturation, bile ducts are formed specifically around the portal vein, indicating that there must be a regionally specific cue for the induction of cholangiocytes from hepatoblasts. Although intrahepatic bile ducts are not visible by E16 in mouse liver, the specification of cholangiocyte lineage from hepatoblasts occurs around E15 in the vicinity of portal vein branches. Alagille syndrome is a human autosomal-dominant developmental disorder that is characterized by defects in multiple organs including impaired differentiation of intrahepatic bile ducts. NOTCH2 and JAGGED1, a ligand for Notch family receptors, have been identified as the genes that cause this disorder ( , 1997) . Consistently, Notch2 is expressed in hepatoblasts, whereas Jagged1 is expressed in periportal mesenchymal cells (Kodama et al., 2004) , and a mouse model with the double mutations of Notch2 and Jagged1 exhibited the paucity of intrahepatic bile ducts that is observed in humans (McCright et al., 2002) . Activation and/or inactivation of Notch signaling in vivo and in vitro have demonstrated that biliary duct mophogenesis and/or differentiation are affected by Notch signaling in the periportal region (Hofmann et al., 2010; Zong et al., 2009 ). These results indicate that Notch signaling plays a critical role for bile duct development. Another important signaling pathway regulating biliary differentiation is TGF-b/Activin. TGF-b2 and TGF-b3 are predominantly expressed in the portal region , and HNF6 (OC-1) and OC-2, onecut transcription factors controlling biliary tract development, modulate expression of a2-macroglobulin and follistatin, which are inhibitors of the TGF-b/Activin pathway, in the parenchymal region (Clotman et al., 2005) . Collectively these studies revealed that various types of fetal liver cells constitute the niche for proliferation and differentiation of hepatoblasts ( Figure 2 ).
Programming and Reprogramming Hepatic Development In Vitro
Reproduction of liver development from embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs) in vitro provides a proof of principle for liver organogenesis and also paves the way for practical use of hepatocytes in drug screening and transplantation settings. Liver transplantation is the only established effective treatment for end-stage liver diseases; however, a shortage of donors limits this treatment. As alternatives to organ (Ogawa et al., 2013) . While there is still room for improvement in terms of maturation, human iPSCs (hiPSCs) can be used for modeling inherited diseases. Rashid et al. (2010) generated iPSCs from patients with a1-anti-trypsin deficiency, familial hypercholesterolemia, and glycogen storage disease and showed that hepatocytes derived from patient-derived iPSCs recapitulate pathological features of the diseases. Furthermore, targeted gene correction of a1-anti-trypsin deficiency in iPSCs restored structure and function of a1-anti-trypsin in iPSC-derived hepatocytes (Yusa et al., 2011) . During the course of the differentiation process from PSCs, hepatoblasts with the potential to differentiate to both hepatocytes and cholangiocytes are expected to emerge. Accordingly, hepatoblast-like cells expressing both hepatocyte and cholangiocyte markers were shown to emerge from PSCs, and they were able to differentiate to hepatocytes and form cysts of cholangiocytes in vitro (Yanagida et al., 2013; Zhao et al., 2009 ). The liver progenitors were expanded on stromal cells in vitro, and transplantation into mouse liver injury models, such as fumarylacetoacetate-hydrolase (Fah) deficiency, allowed engraftment and subsequent differentiation to hepatocytes. In other protocols, by transient adenoviral-induced expression of Hex, a homeotic gene essential for hepatic differentiation, PSC-derived liver progenitors were generated (Takayama et al., 2013) . The Hex-induced cells proliferated and maintained the potential for bidirectional differentiation in vitro and were capable of engraftment in a CCl 4 -injured liver. Recently, induced multipotent progenitor cells (iMPCs), which were generated from partially reprogrammed human fibroblasts, were shown to differentiate to hepatocytes . A similar approach has also been recently used to generate endoderm-like cells capable of differentiating into pancreatic lineages (Li et al., 2014) . Importantly, iMPC-derived endoderm progenitors proliferated extensively, and their differentiation was induced with both small molecules that are known to promote hepatocyte differentiation from PSCs and inhibitors against TGF-b and Notch signaling pathways that are known to promote biliary differentiation, resulting in more differentiated hepatocyte phenotypes as compared to iPSC-derived hepatocytes. Nonetheless, iMPChepatocytes more closely resembled human fetal hepatocytes.
Upon transplantation, iMPC-hepatocytes proliferated extensively in an immunodeficient Fah À/À mouse; however, human serum albumin was not detected for 2 months, indicating that the transplanted cells are still immature and require a substantial maturation period in mouse.
Because the development and differentiation of hepatocytes are supported by various nonparenchymal cells such as endothelial cells and mesenchymal cells, it is likely that addition of those cells to differentiation culture of hepatocytes from ESCs/ iPSCs would improve hepatic functions. Recently, Takebe et al. (2013) developed a coculture system of human iPSCderived hepatic specified definitive endoderm with human umbilical vein endothelial cells (HUVECs) and mesenchymal cells, in which 3D cell clusters are formed. Hepatocytes in the cell clusters expressed many hepatic enzymes. Upon transplantation of the cell clusters into mice, they became vascularized and expressed liver proteins, resulting in improved survival of mice in a toxin injury model. These characteristics suggest that the cell clusters developed in vitro may be considered as liver organoids. However, the cells do not reconstitute the full liver or exhibit long-term function, and their differentiation to cholangiocytes as well as their formation of biliary architecture remains to be demonstrated. Goldman et al. (2013) (Banas et al., 2007; Lee et al., 2004) . More recently, mouse fibroblasts were directly reprogrammed by combined expression of transcription factors, including Hnf4a plus Foxa1, Foxa2, or Foxa3 (Sekiya and Suzuki, 2011) , and Gata4, Hnf1a, and Foxa3 together with inactivation of p19
Arf (Huang et al., 2011 (Huang et al., 2014) or a combination of HNF1A, HNF4A, and HNF6 together with the maturation factors ATF1, PROX1, and CEBPA (Du et al., 2014) . It is notable that different sets of transcription factors can reprogram fibroblasts to hepatocytes. This plasticity is quite reminiscent of the flexible and self-sustaining cross-regulatory network that operates during liver organogenesis (Kyrmizi et al., 2006) , whose incipient activation by any of the sets of reprogramming factors could be sufficient to ignite the self-organizing developmental program to achieve functionally differentiated hepatocytes. Alternatively, it could reflect some difference in fibroblasts and/or culture conditions used for reprogramming. The characteristics of the reprogrammed hepatocytes may not necessarily be the same among these studies and further evaluation of their variance and underlying mechanisms should lead to improvement in reprogramming strategies. The direct reprogramming strategy has also been used to successfully produce hepatoblast-like cells, called induced hepatic stem cells (iHepSCs), from mouse embryonic fibroblasts by introducing Hnf1b and Foxa3 (Yu et al., 2013) . iHepSCs are capable of showing bilineage differentiation in vitro as well as in vivo, and they may potentially offer an expandable source for production of functional hepatocytes. While these efforts to generate functional hepatocytes or progenitor cells from pluripotent/multipotent stem cells or by reprogramming somatic cells are encouraging, practical use of the cells will require a more sophisticated understanding of their terminal differentiation.
Stem Cells in the Normal Adult Liver
Although careful consideration is required as to whether hepatoblasts can truly be called ''stem cells'' in the fetal liver as mentioned earlier, they nevertheless can be regarded as a bona fide progenitor cell population with bilineage differentiation potential in vivo. The situation regarding stem/progenitor cells, however, is further complicated in the adult liver. The nature and role of tissue stem cells in adult organs/tissues can be considered, for simplicity, in the context of two distinct (though closely related) processes; namely, homeostatic maintenance (or tissue turnover) under normal physiological conditions, and tissue repair/regeneration under pathological conditions upon various types of injury. In many tissues/organs, such as the hematopoietic system, intestine, and epidermis, mature differentiated cells have a short life span and their continuous replenishment from the stem cell compartment is critical to maintain structural and functional integrity of the tissue/organ. In contrast, the normal turnover of mature hepatocytes slowly occurs over a period of more than several months (MacDonald, 1961; Magami et al., 2002), and it is therefore questionable whether any stem cell is required for liver maintenance, at least under normal conditions. As such, a widely accepted view in the field argues that maintenance of hepatic tissue under normal physiological conditions is achieved by proliferation of mature hepatocytes that occurs throughout the liver parenchyma (Figure 3) .
The slow turnover rate of hepatocytes makes it practically difficult to apply the long-term label-retaining assay to identify stem cells in vivo in the adult liver. Instead, many recent studies have employed Cre/loxP-mediated genetic marking and lineage tracing systems to characterize the mode of tissue maintenance in the adult mouse liver. A long-lasting, yet still inconclusive, model for hepatocyte turnover is the so-called ''streaming liver hypothesis.'' Based on radiolabeled nucleotide-incorporation assays in the rat liver, Zajicek et al. (1985) claimed that new produced hepatocytes appear in the periportal area (where bile ducts exist) and flow along the hepatic cord toward the pericentral region to continuously replenish the tissue, thus implying the existence of a possible stem cell compartment for homeostatic maintenance of the adult liver. Since then, much evidence has accumulated both in favor and against this hypothesis. The most powerful, and rather surprising, evidence supporting this theory was provided by a genetic lineage tracing study based on the cholangiocyte marker Sox9 (Furuyama et al., 2011) . Using a knockin (KI) mouse strain where the inducible recombinase CreERT2 is inserted into the Sox9 locus, cholangiocytes, but not hepatocytes, were lineage-labeled in the normal adult liver. The label gradually spread out to hepatocytes from the periportal toward pericentral regions and eventually occupied nearly the whole parenchyma after 1 year. The labeled cells also remained present in bile ducts, indicating that the Sox9-expressing cholangiocytes can continuously supply mature hepatocytes for normal tissue turnover while possessing self-renewing activity as well.
However, subsequent studies by other groups employing different types of genetic lineage tracing systems have together provided rather conflicting results with the above report. Studies using a different Sox9-CreERT2 strain (BAC transgenic) (Carpentier et al., 2011) or osteopontin (OPN)-CreERT2 (Españ olSuñ er et al., 2012) to label cholangiocytes did not observe the flow of lineage-labeled cells out of the bile duct. Meanwhile, in studies using a complimentary approach where hepatocytes were initially labeled by a Cre-expressing adeno-associated viral (AAV) vector, contribution of label-negative, nonhepatocytic lineage cells (including cholangiocytes) for the maintenance of parenchymal tissue was not observed (Malato et al., 2011; Yanger et al., 2013) . Overall, the results strongly argue against the streaming liver hypothesis, although they do not completely refute the possibility that the cell of origin for the ''stream'' still exists among periportal hepatocytes, rather than cholangiocytes. Given that cholangiocytes are indeed capable of contributing to parenchymal regeneration under certain types of liver injury conditions, even in the OPN-CreERT2 system (Españ ol-Suñ er et al., 2012), it seems likely that cholangiocytes in the Sox9-CreERT2 KI mouse liver (Furuyama et al., 2011) are somehow biased to differentiate to hepatocytes due to genetic and/or environmental factors, the natures of which are of potential interest. Further studies are needed to resolve this discrepancy and elucidate the exact mode and the underlying mechanisms for physiological maintenance of the liver.
Notably, another study by Iverson et al. (2011) used a unique ''in vivo chronometer'' system based on Alb-Cre-mediated fluorescent color conversion. The result suggested that 0.076% of all hepatocytes in steady-state adult mouse liver were newly born within the previous 4 days from Alb-Cre À cell populations, which could potentially contribute to homeostatic maintenance of liver parenchyma under normal conditions. Because the Alb-Cre activity is induced in hepatoblasts at the fetal stage and continues during their maturation to adult hepatocytes, this result implicates a contribution of nonepithelial lineage cells for hepatocyte maintenance, an intriguing possibility that needs to be further evaluated in other experimental settings. Notwithstanding this complicated situation regarding in vivo identification, many groups have succeeded in isolating ''liver stem cell'' populations from the adult liver based on marker gene expression and flow cytometric cell purification followed by in vitro cultivation (Table 2 and Figure 3) . As is the case with the fetal liver cells, the cells in question can be defined as ''stem cells'' because they are (1) clonogenic with high growth potential, (2) able to inducibly differentiate to both hepatocyte and cholonagiocyte lineages under appropriate culture conditions, and, in some cases, (3) capable of repopulating the liver upon transplantation. Although these cells can be considered as ''potential'' liver stem cells because they can be functionally defined in culture, it remains unclear whether and where they exist in situ in living organisms and how they behave under physiological conditions. It should be noted that potential liver stem cell populations are usually identified as those that are positive for cholangiocyte markers including EpCAM , CD133 (also known as prominin 1) , and the MIC1-1C3 antigen , implicating a possible role of the biliary system as a compartment harboring ''resident'' liver stem cells, if they exist (Figure 3 ). In support of this theory, EpCAM + cells isolated from postnatal human livers, as well as from fetal livers as mentioned earlier, have also been found to contain hepatic stem cells (hHpSCs) that can be defined based on their in vitro function (Schmelzer et al., 2007) . Moreover, multipotential stem/progenitor cells that can give rise to hepatocytes, cholangiocytes, and pancreatic islets have been identified in humans within the peribiliary glands, which are unique epithelial structures in the extrahepatic biliary tree (Cardinale et al., 2011; Carpino et al., 2012) . The corresponding stem/ progenitor cells with similar characteristics and anatomical localization may also be present in mice (Dipaola et al., 2013; Irie et al., 2007) , although they have not been fully characterized.
Stem/Progenitor Cells in Liver Regeneration
The characteristic feature of the liver is its high regenerative capacity, and there has also been debate, with some skepticism, as to whether stem cells are involved in this process. This skepticism is primarily because partial hepatectomy (PHx), the surgical removal of (a) particular lobe(s) of the organ, has long been regarded as the paradigm for experimental analysis of the mechanisms underlying liver regeneration (Michalopoulos, 2007; Michalopoulos and DeFrances, 1997) . The PHx protocol does not cause any injury to the remnant hepatic tissue, and the subsequent regenerative process is considered to be achieved by hypertrophy and proliferation of mature hepatocytes (Miyaoka et al., 2012) , without apparent involvement of any immature stem cell population. Indeed, the results of recent genetic lineage tracing studies in mice support this notion (Españ ol-Suñ er et al., 2012), although a small yet significant proportion of newborn hepatocytes generated from cellular sources other than preexisting hepatocytes has also been suggested (Furuyama et al., 2011; Iverson et al., 2011; Malato et al., 2011) . Nevertheless, the robust regenerative capacity of hepatocytes manifested upon PHx is quite striking and thus might have contributed to a widespread prejudice that the liver does not require any stem/progenitor cells for its regeneration.
While PHx is truly an excellent model to study the process of compensatory growth of the liver and provides useful information relevant to living donor liver transplantation, it does not faithfully recapitulate pathological situations in many human liver diseases, which often involve hepatocyte death and concomitant induction of inflammatory and fibrogenic responses. Under many pathological conditions, such as chronic viral hepatitis, alcoholic liver disease, and nonalcoholic fatty liver disease, unique epithelial cell populations emerge and expand that are not usually observed in a normal liver (Figure 3 ). These cells typically exhibit immature and intermediate phenotypes between hepatocytes and cholangiocytes as determined by morphology and molecular marker expression, and they are considered to be bipotential progenitor cell populations (Fausto, 2004; Roskams et al., 2003 Roskams et al., , 2004 Turá nyi et al., 2010) . Such cell populations have been termed in several different ways, such as ''ductular hepatocytes,'' ''atypical ductal cells,'' ''intermediate hepatobiliary cells,'' or ''hepatic/liver progenitor cells (HPCs/ LPCs).'' The term ''oval cells,'' which was originally coined to describe a specific, ovoid cell population observed in a rat model of liver carcinogenesis (Farber, 1956) , is also often used, particularly in rodent models. Some researchers consider such disease-activated progenitor cell populations as ''liver stem cells'' and, indeed, the term ''oval cells'' is sometimes introduced in literature as a synonym for liver stem cells.
Oval cells are the prototype for adult liver stem/progenitor cell populations, which emerge when the liver is injured under conditions causing defective hepatocyte proliferation (Fausto, 2004) . The most established and reliable protocol currently used to induce oval cells is the 2-acetylaminofluorene (2-AAF)/PHx system in rats, where hepatocyte proliferation is blocked by 2-AAF prior to application of PHx (Evarts et al., 1987) . Ever since their first description by Farber in 1956 (Farber, 1956 ), oval cells have been extensively characterized histologically, which cumulatively suggests that they have bipotential differentiation capability toward both hepatocytes and cholangiocytes. Unfortunately, the lack of genetic lineage tracing systems in rats (as well as the absence of oval-cell-specific markers) has hindered efforts to verify this theory. It is thus quite natural for liver biologists to examine whether oval cells exhibit stem cell activity in mouse models. Although the 2-AAF/PHx system is not applicable in mice, several other liver injury models have been used for ''oval cell'' induction, among which the administration of a 3,5-diethoxycarbonyl-1,4-dihidro-collidine (DDC)-containing diet (Preisegger et al., 1999) or a choline-deficient ethionine-supplemented diet (CDE) (Akhurst et al., 2001 ) are the most extensively used. However, it seems that the blockade of hepatocyte proliferation in these mouse models is not as complete as in the rat 2-AAF/PHx model. Moreover, the injuries sustained in those mouse models are markedly different from that of the 2-AAF/ PHx rat model. The DDC-induced injury is considered to be targeted primarily to the biliary compartment and serves as a model for sclerosing cholangitis and biliary fibrosis (Fickert et al., 2007) , while the CDE protocol induces fatty liver and is sometimes used as a model for nonalcoholic steatohepatitis. As the phenotypic and mechanistic differences among these models as well as other ''oval cell'' induction protocols have become more and more recognized, there is an increasing consensus that the cells induced therein are not exactly the same. Thus, applying the terminology ''oval cell'' in mouse injury models seems to have caused substantial confusion and should be avoided. We suggest that ''LPC'' (liver progenitor cell) is a more appropriate term to broadly describe all the various disease-activated, putative stem/progenitor cell populations that have been observed in the liver regardless of species or injury model.
Characterization of LPCs by Molecular Markers
Despite their potentially different characteristics and ontogeny based on disease etiology, various common markers, such as CK19, EpCAM, and CD133, have been identified to describe LPCs in mice, rats, and humans Rountree et al., 2007; Suzuki et al., 2008; Yovchev et al., 2007) . Sox9, osteopontin, and the MIC1-1C3 antigen are also regarded as equivalent LPC markers, at least in mice (Carpentier et al., 2011; Dorrell et al., 2008 Dorrell et al., , 2011 Matsuo et al., 2011) . Using flow-cytometry-based cell separation methods in conjunction with cell surface markers (e.g., EpCAM, CD133, or MIC1-1C3) or fluorescent reporters (e.g., Sox9-dependent YFP reporter), LPCs can be viably isolated and subjected to in vitro culture to be evaluated for their proliferation and differentiation potentials. Collectively, such isolation and culture methods have demonstrated that LPCs contained cells that are clonogenic in vitro and can differentiate into both hepatocytic and cholangiocytic lineages under certain culture conditions (Table 2 and Figure 3) . These results strongly suggest that LPCs, when strictly defined by clonogenicity and in vitro differentiation potential, indeed contain bipotential stem/progenitor cells in the liver. Importantly, cholangiocytes isolated from the normal liver based on the same molecular markers also qualitatively exhibit the same potential in vitro. Thus, it remains uncertain whether in vitro assays adequately and specifically evaluate the potential of diseaseactivated LPCs distinct from the ''potential'' liver stem cells residing in the biliary compartment under normal conditions. Several studies have identified possible LPC-specific markers that can distinguish LPCs form cholangiocytes in the normal liver. Trop2 (Tacstd2), a transmembrane molecule that is structurally related to and is a paralog of EpCAM, has been found to be expressed exclusively in LPCs under the DDC-induced injury condition, but not in cholangiocytes in the normal liver ). Thus, Trop2 may serve as a genuine LPC-specific marker and if so, it would be advantageous for further characterization of LPCs. The clonogenicity and differentiation potential of the Trop2 + cells as well as experiments tracing their fate have not yet been examined. The transcription factor Foxl1 has been identified as another potential LPC-specific marker, in that a transgenic (Tg) mouse line expressing Cre recombinase under the control of the Foxl1 promoter has been used to demonstrate that both hepatocytes and cholangiocytes were derived from Foxl1 + LPCs under certain injury conditions (Sackett et al., 2009) . The Cre recombinase used in the Foxl1-Cre Tg mouse is constitutively expressed and cannot be temporally regulated, so it remains undetermined whether single Foxl1 + LPCs can clonally differentiate into these two lineages or whether the Foxl1 + population contains distinct hepatocytic and cholangiocytic progenitors. More recently, Lgr5, a well-established marker for stem cells in the intestine as well as several other tissues/ organs, has also been demonstrated to be expressed specifically in damage-induced LPCs in the liver using Lgr5-LacZ and Lgr5-CreERT2 KI mice (Huch et al., 2013) . Lgr5 + cells can be clonally expanded as transplantable organoids in a 3D culture system, and those organoids retain many characteristics of the original epithelial architecture. The relationship between Lgr5 + cells and those expressing the authentic LPC markers such as CK19 and EpCAM has not been clearly determined. In addition, a major drawback for Foxl1 and Lgr5 is that expression of the endogenous genes/proteins in LPCs has not been clearly demonstrated thus far, and assays currently rely on the use of those particular Tg and KI mouse lines. It should be emphasized that the Foxl1 and Lgr5 markers are not expressed prior to damage and thus cannot be used to prelabel the cells that arise during regeneration. Nevertheless, further characterization of such cell populations should provide unique and more versatile LPC-specific markers and genetic tools, with which clonal analyses of LPCs may be achieved in vivo.
Origin of LPCs
LPCs are apparently a ''facultative'' stem/progenitor cell population that emerge and are recognized only under damage conditions, and the cell of origin for this subset of cells is of significant interest. Based on the histological analyses of rat oval cells, it has long been proposed that the canal of Hering, the junctional structure connecting bile canaliculi formed by hepatocytes with bile ducts lined by cholangiocytes, is the origin of these cells (Paku et al., 2001) (Figure 3 ). This notion is consistent with the fact that LPCs almost always emerge from the periportal area. Furthermore, given its anatomical location between cholangiocyte and hepatocyte populations, it seems reasonable to assume that this structure may serve as a niche for putative progenitor cell populations that are destined to differentiate toward these two cell lineages. Hence, the concept that the canal of Hering may serve as the origin of LPCs is widely accepted, though it is not formally proven to be applicable to such progenitors in general. This notion further suggests that the canal of Hering serves as a niche for a specialized precursor cell population for LPCs, which some researchers would prefer to denote as ''liver stem cells.'' Unfortunately, however, direct proof for this idea is still hampered by lack of any specific marker for such cells as well as the cells constituting the canal of Hering. As mentioned earlier, in vitro assays have clearly detected the presence of potential liver stem cells with clonogenicity and bilineage differentiation potential in the biliary compartment, even in the normal liver. It is of considerable interest to determine whether they actually correspond to and play a role as the reserve stem cells in vivo to produce LPCs once the liver is injured.
While much effort is still underway to identify putative, specific markers for the cell of origin for LPCs, Cre/loxP-mediated genetic lineage tracing studies in mice have been done by labeling ''mature'' liver epithelial cells based on well-established differentiation markers. Consistent with the fact that most of the molecular markers for LPCs are also expressed in cholangiocytes, lineage tracing studies employing cholangiocyte-specific Cre driver strains have collectively indicated that LPCs identified under liver injury conditions can be derived from cholangiocytes in the normal liver Españ ol-Suñ er et al., 2012; Furuyama et al., 2011) . It is not clear, however, whether most if not all cholangiocytes can equally or similarly behave as precursors for LPCs, or if there is a certain type of specialized ''LPC cell-of-origin'' subpopulation located somewhere among cholangiocytes. For the latter possibility, the cholangiocytes adjacent to hepatocytes that form the canal of Hering would be a plausible candidate. Notably, the potential contribution of hepatocytes as an origin for LPCs can also be considered. In a study using mice with chimeric livers generated from the transplantation of wild-type (Fah +/+ ) mouse-derived hepatocytes to Fah the DDC injury were found to be of host (Fah À/À ) origin and not derived from repopulated (wild-type) hepatocytes, suggesting that hepatocytes are not likely to act as the cell of origin for LPCs (Wang et al., 2003) . However, more recent studies employing lineage tracing approaches have demonstrated that hepatocytes can be reprogrammed to LPCs under certain liver injury conditions including the DDC model (Yanger et al., 2013) . Again, it is unclear whether most if not all mature hepatocytes possess such plasticity or whether there are specific subsets of hepatocytes, such as those lining a part of the canal of Hering, that can be converted to LPCs.
In addition to the phenotypic and ontogenic characterization of LPCs, many recent studies focus on elucidating the cellular and molecular frameworks for their regulatory mechanisms and have identified several key signaling pathways. Similar to the various extrahepatic tissue stem/progenitor cells, a set of developmental ''toolkit'' genes, including Wnt (Apte et al., 2008; Boulter et al., 2012; Hu et al., 2007; Itoh et al., 2009; Yang et al., 2008) , Notch (Boulter et al., 2012; Fiorotto et al., 2013; Kitade et al., 2013) , and FGF (Takase et al., 2013) , have been shown to play a relevant role in LPC regulation. Consistent with the notion that chronic liver injury conditions where LPCs are activated usually accompany inflammatory responses, involvement of several inflammatory cytokines, such as tumor necrosis factor (TNF)-alpha, interleukin-6, and interferongamma, has also been reported (Akhurst et al., 2005; Knight et al., 2000; Yeoh et al., 2007) . Among those factors, TNF-related WEAK inducer of apoptosis (TWEAK) and FGF7 are of particular interest because they are capable of inducing de novo activation of LPCs. Forced expression of either of these factors in the normal liver can lead to induction and expansion of cells reminiscent of LPCs, even in the absence of any liver injury regimen (Jakubowski et al., 2005; Takase et al., 2013) . This phenomenon strongly suggests that the cell of origin for LPCs is responsive to these extracellular signals. Other growth factors, such as HGF and EGF, have also been implicated in regulating proliferation and/or differentiation of LPCs (Ishikawa et al., 2012; Kitade et al., 2013) . These humoral factors may be of potential use in therapeutic strategies to counter liver disease by enhancing the inherent regenerative capacity within the organ.
Cancer Stem Cells in the Liver and Their Origins
Tumors exhibit considerable heterogeneity even though they arise clonally. This heterogeneity is thought to result from hierarchical organization of the tumor cells by a subset of cells with stem cell features, i.e., cancer stem cells (CSCs) with the potential for self-renewal and differentiation (Kreso and Dick, 2014) . Because elimination of CSCs is necessary for eradication of tumors, much attention has been given to the identification of CSCs for developing effective therapeutic drugs. Besides such a practical point of view, the origin of CSCs, an abnormal stem cell type, is of considerable interest in stem cell biology. Liver cancer is an aggressive disease with a poor outcome. Among primary liver cancers, hepatocellular carcinoma (HCC) accounts for 70%-85% of the cases and intrahepatic cholangiocarcinoma (ICC) is the second most frequent type of liver cancer. Both HCC and ICC are heterogenous in their cellular morphology and clinical outcome. Mixed HCC-cholangiocellular carcinoma (HCC-CCC) is a rare form of liver cancer exhibiting both hepatocellular and cholangiocellular features, reminiscent of liver stem/progenitor cells. Intriguingly, forced expression of polycomb group protein Bmi1 or b-catenin in hepatoblasts allowed their expansion in vitro, and transplantation of clonally expanded cells produced tumors with histological features of combined HCC-CCC, suggesting that liver stem/progenitor cells may be the origin of such tumors (Chiba et al., 2007) . However, the vast majority of human HCCs arise from chronic infection with hepatitis virus with HCC subsequently developing after a long latency, suggesting that HCC is derived from mature hepatocytes. HCC exhibits considerable heterogeneity and often contains cells expressing liver stem/progenitor markers, e.g., EpCAM, CD133, CD44, CD24, and DLK1 (reviewed in Yamashita and Wang, 2013) . Consistently, recent studies have identified the oncofetal gene SALL4, which encodes a transcription factor functioning in fetal liver development , as a prognostic marker for a progenitor subclass of hepatocellular carcinoma with an aggressive phenotype (Oikawa et al., 2013; Yong et al., 2013; Zeng et al., 2014) . Interestingly, some cell lines derived from HCC such as Huh7 also show heterogeneity and a subpopulation expressing some of these stem/progenitor cell markers or excreting Hoechst dye (side population) were shown to develop tumors in immunodeficient mice, indicating that they are tumor initiating cells, a key characteristic of CSCs (Chiba et al., 2006; Haraguchi et al., 2010) . However, because most of previous studies showing tumor-initiating activity were based on cell lines, isolation of fresh cells with stem cell markers from patient tissues and demonstration of tumor-initiating activity is necessary for precise identification of liver CSCs. Because stem/progenitor cell markers are often expressed in HCC, mature hepatocytes may regress to an immature stage during tumorigenesis. Alternatively, there may be immature hepatocytes infected with virus, which then give rise to tumors. Intriguingly, recent studies using cell fate tracing of hepatocytes demonstrated that ICC originates from hepatocytes rather than cholangiocytes and that Notch and Akt signaling cooperate to convert hepatocytes into biliary cells that act as precursors of ICCs (Fan et al., 2012; Sekiya and Suzuki, 2012) . While it remains unknown whether stem/progenitor cells emerge transiently during the conversion, the plasticity of hepatocytes provides insight into the mechanism for pathogenesis as a consequence of defective liver regeneration.
Conclusion
Hepatocytes and cholangiocytes are two types of liver epithelial cells and the cell type that eventually gives rise to both epithelial cells has been considered to be the liver stem cell. In fetal, adult, and diseased livers, there are clearly some cells with the potential to proliferate and differentiate to both cell types in vitro, indicating the presence of ''potential'' stem cells in liver. However, if the liver stem cell is defined by the ability for continuous selfrenewal and contribution to both type of epithelial cells in vivo, it is questionable whether liver stem cells are present in the body. Hepatoblasts in fetal liver proliferate but also change their phenotype throughout development, so they are more appropriately defined as progenitor cells. In normal adult liver, the presence of a resident self-renewable stem cell still remains to be demonstrated. In injured and regenerating livers, proliferating cells around the portal vein are also better referred to as progenitor cells rather than stem cells until any solid evidence showing their clonal differentiation to both hepatocytes and cholangiocytes in vivo is provided. Because there is substantial variability among definitions and identification strategies, extreme caution and consideration should be employed when comparing results from the literature that refer to ''liver stem cells,'' as the characteristics of these cells may vary according to the way they are defined in each study.
